Amicus Therapeutics (FOLD) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amicus Therapeutics Announces Second Quarter 2015 Financial Results and Corporate Updates
August 5, 2015 4:01 PM EDTMarketing Submissions for Galafold® (migalastat HCl) for Fabry Disease Under Review in Europe and on Track for Filing in 2H15 in United States
2Q15 Equity Financing Significantly Strengthens Balance Sheet; More Than $350M Cash on Hand
International Commercial Leadership Team Nearly Complete
Phase 1/2 Clinical Study Initiation of Next-Generation Pompe ERT in 2H15
CRANBURY, N.J., Aug. 5, 2015 (GLOBE NEWSWIRE) --... More
